Current status of the Finnish boron neutron capture therapy (BNCT) project

Iiro Auterinen; Carita Aschan; Judit Benczik; Markus Färkkilä; Pekka Hiismäki; Karoliina Kaita; Markku Kallio; Antti Kosunen; Martti Kulvik; M. Kärkkäinen; P. Ryynänen; Sauli Savolainen; Tiina Seppälä; Tom Serén; Vesa Tanner; Mika Toivonen; Jyrki Vähätalo; Hanna Ylä-Mella

Current status of the Finnish boron neutron capture therapy (BNCT) project

Iiro Auterinen, Carita Aschan, Judit Benczik, Markus Färkkilä, Pekka Hiismäki, Karoliina Kaita, Markku Kallio, Antti Kosunen, Martti Kulvik, M. Kärkkäinen, P. Ryynänen, Sauli Savolainen, Tiina Seppälä, Tom Serén, Vesa Tanner, Mika Toivonen, Jyrki Vähätalo, Hanna Ylä-Mella

Research output: Chapter in Book/Report/Conference proceeding › Conference abstract in proceedings › Scientific

Abstract

A research group to carry out clinical application of BNCT was established in Finland in the early 1990's. The neutron irradiations will take place at the Finnish research reactor (FiR 1) operated by VTT in Otaniemi. In April 1996 the new FLUENTALtm neutron moderator developed by VTT was installed and in September a conical beam collimator. Neutron field and dosimetric measurements have confirmed that the epithermal neutron field is suitable for human treatments. In October a thorough renovation of the reactor building has started. The ground and first floor will be converted into a BNCT research and treatment facility. The Monte Carlo based INEL NCT dose planning program rtt_MC has been used in the determination of the brain substitute materials for head phantoms. The program is also used in the healthy tissue tolerance studies. Other efforts in dosimetry include studying the suitability of TL detectors for BNCT. To determine the boron capture dose distribution the boron distribution in the tumour and in the other tissues has to be known in addition to the thermal neutron field. The current efforts on boron bulk-analysis are focused on the methods ICP-AES, PGNA and PIGE. In order to analyse boron distribution at cellular level SIMS will he used combined with freeze-drying and cryosectioning, thus preserving the original boron distribution in the samples. Boron distribution determination in vivo is pursued by radiolabelling boron carriers. Normal tissue tolerance studies in co-operation with CRC Radiobiology Unit, Oxford, England, will contribute towards the verification of the treatment planning, radiation doses, biological effects and radiation safety of BNCT before proceeding to therapies of patients. Boron carrier biodistribution studies of boronophenytalanine (BPA) will be completed in 1998, with data available for the patient treatments.

Original language	English
Title of host publication	Proceedings of the XXXI Annual Conference of the Finnish Physical Society
Subtitle of host publication	Abstracts
Editors	Eero Rauhala, M.E. Sainio
Place of Publication	Helsinki
Publisher	University of Helsinki
ISBN (Print)	951-45-7639-X
Publication status	Published - 1997
MoE publication type	Not Eligible
Event	XXXI Annual Conference of the Finnish Physical Society - Helsinki, Finland Duration: 13 Mar 1997 → 15 Mar 1997

Publication series

Series	University of Helsinki: Department of Physics. Report Series in Physics
Volume	262
ISSN	0355-5801

Conference

Conference	XXXI Annual Conference of the Finnish Physical Society
Country/Territory	Finland
City	Helsinki
Period	13/03/97 → 15/03/97

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Auterinen, I., Aschan, C., Benczik, J., Färkkilä, M., Hiismäki, P., Kaita, K., Kallio, M., Kosunen, A., Kulvik, M., Kärkkäinen, M., Ryynänen, P., Savolainen, S., Seppälä, T., Serén, T., Tanner, V., Toivonen, M., Vähätalo, J., & Ylä-Mella, H. (1997). Current status of the Finnish boron neutron capture therapy (BNCT) project. In E. Rauhala, & M. E. Sainio (Eds.), Proceedings of the XXXI Annual Conference of the Finnish Physical Society: Abstracts Article 12.01/87.00 University of Helsinki.

Auterinen, Iiro ; Aschan, Carita ; Benczik, Judit et al. / Current status of the Finnish boron neutron capture therapy (BNCT) project. Proceedings of the XXXI Annual Conference of the Finnish Physical Society: Abstracts. editor / Eero Rauhala ; M.E. Sainio. Helsinki : University of Helsinki, 1997. (University of Helsinki: Department of Physics. Report Series in Physics, Vol. 262).

@inbook{3acc2457fb7a4537abddc924fc0a5906,

title = "Current status of the Finnish boron neutron capture therapy (BNCT) project",

abstract = "A research group to carry out clinical application of BNCT was established in Finland in the early 1990's. The neutron irradiations will take place at the Finnish research reactor (FiR 1) operated by VTT in Otaniemi. In April 1996 the new FLUENTALtm neutron moderator developed by VTT was installed and in September a conical beam collimator. Neutron field and dosimetric measurements have confirmed that the epithermal neutron field is suitable for human treatments. In October a thorough renovation of the reactor building has started. The ground and first floor will be converted into a BNCT research and treatment facility. The Monte Carlo based INEL NCT dose planning program rtt_MC has been used in the determination of the brain substitute materials for head phantoms. The program is also used in the healthy tissue tolerance studies. Other efforts in dosimetry include studying the suitability of TL detectors for BNCT. To determine the boron capture dose distribution the boron distribution in the tumour and in the other tissues has to be known in addition to the thermal neutron field. The current efforts on boron bulk-analysis are focused on the methods ICP-AES, PGNA and PIGE. In order to analyse boron distribution at cellular level SIMS will he used combined with freeze-drying and cryosectioning, thus preserving the original boron distribution in the samples. Boron distribution determination in vivo is pursued by radiolabelling boron carriers. Normal tissue tolerance studies in co-operation with CRC Radiobiology Unit, Oxford, England, will contribute towards the verification of the treatment planning, radiation doses, biological effects and radiation safety of BNCT before proceeding to therapies of patients. Boron carrier biodistribution studies of boronophenytalanine (BPA) will be completed in 1998, with data available for the patient treatments.",

author = "Iiro Auterinen and Carita Aschan and Judit Benczik and Markus F{\"a}rkkil{\"a} and Pekka Hiism{\"a}ki and Karoliina Kaita and Markku Kallio and Antti Kosunen and Martti Kulvik and M. K{\"a}rkk{\"a}inen and P. Ryyn{\"a}nen and Sauli Savolainen and Tiina Sepp{\"a}l{\"a} and Tom Ser{\'e}n and Vesa Tanner and Mika Toivonen and Jyrki V{\"a}h{\"a}talo and Hanna Yl{\"a}-Mella",

year = "1997",

language = "English",

isbn = "951-45-7639-X",

series = "University of Helsinki: Department of Physics. Report Series in Physics",

publisher = "University of Helsinki",

editor = "Eero Rauhala and M.E. Sainio",

booktitle = "Proceedings of the XXXI Annual Conference of the Finnish Physical Society",

address = "Finland",

note = "XXXI Annual Conference of the Finnish Physical Society ; Conference date: 13-03-1997 Through 15-03-1997",

}

Auterinen, I, Aschan, C, Benczik, J, Färkkilä, M, Hiismäki, P, Kaita, K, Kallio, M, Kosunen, A, Kulvik, M, Kärkkäinen, M, Ryynänen, P, Savolainen, S, Seppälä, T, Serén, T, Tanner, V, Toivonen, M, Vähätalo, J & Ylä-Mella, H 1997, Current status of the Finnish boron neutron capture therapy (BNCT) project. in E Rauhala & ME Sainio (eds), Proceedings of the XXXI Annual Conference of the Finnish Physical Society: Abstracts., 12.01/87.00, University of Helsinki, Helsinki, University of Helsinki: Department of Physics. Report Series in Physics, vol. 262, XXXI Annual Conference of the Finnish Physical Society, Helsinki, Finland, 13/03/97.

Current status of the Finnish boron neutron capture therapy (BNCT) project. / Auterinen, Iiro; Aschan, Carita; Benczik, Judit et al.
Proceedings of the XXXI Annual Conference of the Finnish Physical Society: Abstracts. ed. / Eero Rauhala; M.E. Sainio. Helsinki: University of Helsinki, 1997. 12.01/87.00 (University of Helsinki: Department of Physics. Report Series in Physics, Vol. 262).

Research output: Chapter in Book/Report/Conference proceeding › Conference abstract in proceedings › Scientific

TY - CHAP

T1 - Current status of the Finnish boron neutron capture therapy (BNCT) project

AU - Auterinen, Iiro

AU - Aschan, Carita

AU - Benczik, Judit

AU - Färkkilä, Markus

AU - Hiismäki, Pekka

AU - Kaita, Karoliina

AU - Kallio, Markku

AU - Kosunen, Antti

AU - Kulvik, Martti

AU - Kärkkäinen, M.

AU - Ryynänen, P.

AU - Savolainen, Sauli

AU - Seppälä, Tiina

AU - Serén, Tom

AU - Tanner, Vesa

AU - Toivonen, Mika

AU - Vähätalo, Jyrki

AU - Ylä-Mella, Hanna

PY - 1997

Y1 - 1997

N2 - A research group to carry out clinical application of BNCT was established in Finland in the early 1990's. The neutron irradiations will take place at the Finnish research reactor (FiR 1) operated by VTT in Otaniemi. In April 1996 the new FLUENTALtm neutron moderator developed by VTT was installed and in September a conical beam collimator. Neutron field and dosimetric measurements have confirmed that the epithermal neutron field is suitable for human treatments. In October a thorough renovation of the reactor building has started. The ground and first floor will be converted into a BNCT research and treatment facility. The Monte Carlo based INEL NCT dose planning program rtt_MC has been used in the determination of the brain substitute materials for head phantoms. The program is also used in the healthy tissue tolerance studies. Other efforts in dosimetry include studying the suitability of TL detectors for BNCT. To determine the boron capture dose distribution the boron distribution in the tumour and in the other tissues has to be known in addition to the thermal neutron field. The current efforts on boron bulk-analysis are focused on the methods ICP-AES, PGNA and PIGE. In order to analyse boron distribution at cellular level SIMS will he used combined with freeze-drying and cryosectioning, thus preserving the original boron distribution in the samples. Boron distribution determination in vivo is pursued by radiolabelling boron carriers. Normal tissue tolerance studies in co-operation with CRC Radiobiology Unit, Oxford, England, will contribute towards the verification of the treatment planning, radiation doses, biological effects and radiation safety of BNCT before proceeding to therapies of patients. Boron carrier biodistribution studies of boronophenytalanine (BPA) will be completed in 1998, with data available for the patient treatments.

AB - A research group to carry out clinical application of BNCT was established in Finland in the early 1990's. The neutron irradiations will take place at the Finnish research reactor (FiR 1) operated by VTT in Otaniemi. In April 1996 the new FLUENTALtm neutron moderator developed by VTT was installed and in September a conical beam collimator. Neutron field and dosimetric measurements have confirmed that the epithermal neutron field is suitable for human treatments. In October a thorough renovation of the reactor building has started. The ground and first floor will be converted into a BNCT research and treatment facility. The Monte Carlo based INEL NCT dose planning program rtt_MC has been used in the determination of the brain substitute materials for head phantoms. The program is also used in the healthy tissue tolerance studies. Other efforts in dosimetry include studying the suitability of TL detectors for BNCT. To determine the boron capture dose distribution the boron distribution in the tumour and in the other tissues has to be known in addition to the thermal neutron field. The current efforts on boron bulk-analysis are focused on the methods ICP-AES, PGNA and PIGE. In order to analyse boron distribution at cellular level SIMS will he used combined with freeze-drying and cryosectioning, thus preserving the original boron distribution in the samples. Boron distribution determination in vivo is pursued by radiolabelling boron carriers. Normal tissue tolerance studies in co-operation with CRC Radiobiology Unit, Oxford, England, will contribute towards the verification of the treatment planning, radiation doses, biological effects and radiation safety of BNCT before proceeding to therapies of patients. Boron carrier biodistribution studies of boronophenytalanine (BPA) will be completed in 1998, with data available for the patient treatments.

M3 - Conference abstract in proceedings

SN - 951-45-7639-X

T3 - University of Helsinki: Department of Physics. Report Series in Physics

BT - Proceedings of the XXXI Annual Conference of the Finnish Physical Society

A2 - Rauhala, Eero

A2 - Sainio, M.E.

PB - University of Helsinki

CY - Helsinki

T2 - XXXI Annual Conference of the Finnish Physical Society

Y2 - 13 March 1997 through 15 March 1997

ER -

Auterinen I, Aschan C, Benczik J, Färkkilä M, Hiismäki P, Kaita K et al. Current status of the Finnish boron neutron capture therapy (BNCT) project. In Rauhala E, Sainio ME, editors, Proceedings of the XXXI Annual Conference of the Finnish Physical Society: Abstracts. Helsinki: University of Helsinki. 1997. 12.01/87.00. (University of Helsinki: Department of Physics. Report Series in Physics, Vol. 262).

Current status of the Finnish boron neutron capture therapy (BNCT) project

Abstract

Publication series

Conference

UN SDGs

Fingerprint

Cite this